The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma
Open accessAbstract
The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor sites accurately and properly activate complex immune responses. Herein, we design and prepare a kind of chemotactic nanomotor loaded with brain endothelial cell targeting agent angiopep-2 and anti-tumor drug (Lonidamine modified with mitochondrial targeting agent triphenylphosphine, TLND). Reactive oxygen species and inducible nitric oxide synthase (ROS/iNOS), which are specifically highly expressed in glioblastoma microenvironment, are used as chemoattractants to induce the chemotactic behavior of the nanomotors. We propose a precise targeting strategy of brain endothelial cells-tumor cells-mitochondria. Results verified that the released NO and TLND can regulate the immune circulation through multiple steps to enhance the effect of immunotherapy, including triggering the immunogenic cell death of tumor, inducing dendritic cells to mature, promoting cytotoxic T cells infiltration, and regulating tumor microenvironment. Moreover, this treatment strategy can form an effective immune memory effect to prevent tumor metastasis and recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
Dual-responsive biohybrid neutrobots for active target delivery
Zhang, H., Li, Z., Gao, C., Fan, X., Pang, Y., Li, T., Wu, Z., Xie, H., & He, Q. (2021) · Science Robotics · doi:10.1126/scirobotics.aaz9519 · Cited by 518
Self-citationT cell receptor signalling in the control of regulatory T cell differentiation and function
Li, M. O., & Rudensky, A. Y. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.26 · Cited by 493
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
Cited by
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma
Gao, Y., Mao, M., Li, Y., Xuan, M., Wu, Y., & He, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-60422-z · Cited by 42
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Zhang, Y., Kang, X., Ma, J., Li, J., Chen, W., Yang, S., Li, W., Shi, Y., & Qi, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202419395 · Cited by 20
Metadata
- Authors
- Chen, H., Li, T., Liu, Z., Tang, S., Tong, J., Tao, Y., Zhao, Z., Li, N., Mao, C., Shen, J., & Wan, M.
- Venue
- Nature Communications
- Published
- 2023-02-20
- Volume
- 14
- Issue
- 1
- Pages
- 941-941
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4321369852
- Cited by
- 197
- References
- 6
- FWCI
- 20.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. https://app.cochat.ai/papers/10.1038/s41467-022-35709-0
- The paper
- Chen, H., Li, T., Liu, Z., Tang, S., Tong, J., Tao, Y., Zhao, Z., Li, N., Mao, C., Shen, J., & Wan, M. (2023). A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. Nature Communications. https://doi.org/10.1038/s41467-022-35709-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.